Areas of interest
Explore Bristol Myers Squibb's areas of interest and research priorities, highlighting opportunities for collaboration and innovation across therapeutic areas and scientific disciplines.
Our approach to external innovation
Bristol Myers Squibb is focused on discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. External innovation and partnering are critical drivers of our strategy. We seek collaborations in our core therapeutic areas and pursue differentiated platforms. We focus on breakthrough science that has the potential to be first- or best-in-class and address areas of high unmet medical need.
Therapeutic areas
Bristol Myers Squibb has pioneered breakthrough medicines that have changed survival expectations for patients with cancer. From the early breakthroughs such as taxane-based chemotherapy to transforming the treatment landscape by harnessing the body’s immune system to fight cancer, we have created an extensive portfolio of investigational therapeutics and approved medicines.
- We leverage our expertise in foundational cancer biology and application of translational approaches to benefit patients across all stages of disease.
- We are pursuing bold, novel therapies that focus on disease biology of cancers with high unmet need.
- Our diverse and broad toolbox of modalities allows us to match the right therapeutic modality to a molecular mechanism of action.
- We are investigating tumor-intrinsic and -extrinsic pathways, including factors within the immune system, to enable novel cancer therapies.
Watch this video to hear from R&D Leaders on our solid tumors areas of interest
Areas of interest include, but are not limited to, the following:
- Emerging modalities such as antibody-drug conjugates, radiopharmaceuticals, immune cell engagers and cell therapies
- Continued investment in targeted protein degrader platform
- Leveraging cell surface vulnerabilities with modalities including antibody-drug conjugates
- Tumor-intrinsic biology with clear patient selection strategy
- Historically intractable targets to develop disruptive and innovative therapeutics
- Novel innate and adaptive immune mechanisms
- Next-generation therapies with differentiated safety and efficacy profiles
- Therapies that address tumor-intrinsic vulnerabilities and primary or acquired mechanisms of resistance to standard of care
Bristol Myers Squibb has pioneered groundbreaking medicines and is committed to sustaining its strong leadership and legacy in the development of innovative therapeutics for treating patients with malignant and benign hematological conditions.
- Our focus is on multiple myeloma, lymphoma and CLL, AML, MDS, MPNs (e.g., myelofibrosis) and non-malignant conditions (e.g., thalassemias).
Areas of interest include, but are not limited to, the following:
- Targeted protein degradation/protein homeostasis
- Novel modalities, including ADCs, degrader-antibody conjugates (DACs), immune cell engagers and other novel antibody constructs
- Targeting molecularly defined patient segments
- Next-generation therapies with differentiated safety and clinical efficacy
- Novel therapeutic targets/ pathways and combinations
- Cell therapies, including novel targets, next-generation engineering and in vivo approaches
- Targeting pathways of resistance
Watch this video to hear from R&D leaders on our hematology areas of interest
Bristol Myers Squibb is pursuing bold science to deliver life-changing medicines across rheumatology and pulmonology, to elevate new standards of care and help restore what immune-mediated diseases have taken away — empowering patients and their loved ones to take back their lives.
- Our team has a strong history of pioneering research on novel pathways and approaches, resulting in new therapies that modulate the body’s immune response to treat disease.
- Today, Bristol Myers Squibb’s immunology franchise encompasses several marketed products and a pipeline in clinical development, including in systemic lupus erythematosus (SLE), pulmonary fibrosis and other autoimmune, immune-driven and fibrotic diseases with high unmet needs.
- Our strategic research approach aims to address the root cause of immune-mediated diseases by focusing on resetting the immune system – specifically resetting pathogenic memory B and T cell compartments. With the goal to achieve transformational efficacy, durable remissions, and ultimately, cures, we are also emphasizing the preservation and restoration of organ function through targeting tissue repair mechanisms and addressing fibrosis.
Watch this video to hear from R&D leaders on our immunology areas of interest.
Areas of interest include, but are not limited to, the following:
- Agents, including cell therapies and other advanced therapies, for rheumatic diseases that are designed to eliminate pathogenic immune memory cells including effector B and T cells
- Therapeutic candidates for pulmonary diseases (e.g., pulmonary fibrosis, chronic obstructive pulmonary disease [COPD] and interstitial lung disease [ILD]) that act by promoting tissue repair and reversal of fibrosis
- Agents designed to restore immune and tissue homeostasis. Mechanisms of interest include modulation of inflammatory responses, protection of epithelial integrity and normalization of fibroblast activation
- Novel therapeutic modalities that selectively target tissue-restricted or genetically validated molecular pathways
- Biomarkers of disease activity that enable patient stratification and provide pharmacodynamic readouts predictive of clinical efficacy, with particular emphasis on biomarker-enabled programs for relevant disease indications
Leveraging longstanding expertise, Bristol Myers Squibb has pioneered some of the most significant advancements in cardiovascular care and delivered transformational results for patients. We are building on our more than 70-year legacy to take cardiovascular research to the next level, elevate new standards of care and develop first-in-class and best-in-class therapies. Our precision medicine approach involves a deep understanding of genetics and causal human biology to identify the right targets and best treatment approaches with the hope of creating better patient outcomes. These include disease-modifying medicines that are designed to help patients living with thrombotic conditions, heart failure, cardiomyopathies and residual risk of atherosclerotic cardiovascular disease in ways that were never possible before.
Watch this video to hear from R&D leaders on our cardiovascular areas of interest.
Areas of interest include, but are not limited to, the following:
- Novel mechanisms across the spectrum of heart failure, including cardiorenal disease modification and reverse remodeling of the left and right ventricles
- Agents that address vascular disease beyond thrombosis, including stroke, vascular dementia and peripheral vascular disease
- Novel cardiomyopathy targets, including genetically defined and protein misfolding disease
- Agents addressing cardiac myocyte proteotoxicity, sarcomere function modulators and next-generation approaches for amyloid cardiomyopathy
- Cardiac-specific delivery of modalities, such as lipid nanoparticles or heart-targeted ligands, to improve potency while limiting off-target exposure
- Agents that address residual atherosclerosis risk driven by poorly treated dyslipidemias, visceral adiposity and/or plaque inflammation
- Novel mechanisms to treat arrhythmias, including atrial fibrillation
- Translational tools for patient selection within more precisely defined patient populations
Bristol Myers Squibb is committed to the development of transformational therapeutics for patients living with neurodegenerative and neuropsychiatric diseases, with a focus on conditions with critical unmet needs. We work to develop life-changing medicines that modify disease and treat symptoms to improve quality of life.
- We have established an innovative neuroscience pipeline with assets across a breadth of modalities and pathways, accelerated by our growing leadership in neuropsychiatry. Our agile neuroscience research and development model is designed to cultivate a growing pipeline of differentiated drug candidates and deliver meaningful therapies for patients.
- We combine internal expertise — including industry-leading discovery and development capabilities, an in-house neuroimaging program, world-class clinical trial operations capabilities and a strong emphasis on translational research — with flexible external partnerships to identify and advance the most promising scientific innovation happening across the globe and deliver transformational results for our patients.
Watch this video to hear from R&D leaders on our neuroscience areas of interest.
Areas of interest include, but are not limited to, the following:
- Disease-modifying therapies for Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), repeat expansion diseases, progressive forms of multiple sclerosis, neuromuscular and movement disorders
- Novel therapies for psychiatric conditions such as schizophrenia, major depressive disorder, anxiety disorders and bipolar disorder where there are symptom domains of high unmet medical need and potential to improve patient outcomes
- Novel therapies for neuropsychiatric symptoms associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease psychosis and Alzheimer’s disease agitation
- Novel therapies to improve cognition in neuropsychiatric disorders
- Targets that modulate brain circuitry underlying psychiatric and neuropsychiatric diseases, protein homeostasis, protein clearance, immune system biology, and neuroinflammation and that reduce, eliminate or clear neurotoxic proteins
- Emerging technologies (RNA, gene regulation) that, when matched to underlying disease genetics, can deliver a portfolio with a high probability of success to address unmet medical needs
- Novel brain transporter technology to improve delivery of medicines across the blood-brain barrier
- Cell therapies, TCEs, in vivo approaches for neuroimmune regulation and reset or CNS neuron replacement for conditions such as Parkinson’s disease
- Translational tools
- Novel translational biomarkers (Tissue-, imaging-, sensor-based) for detection, staging and monitoring progression of early disease
- Novel methodologies for establishing clinical meaningfulness of novel drug candidates as early as possible in disease
Cross-therapeutic areas of focus
Bristol Myers Squibb is committed to building a leadership position in cell therapy by leveraging unparalleled disease expertise, manufacturing capability and scale and a portfolio of first/best-in-class assets.
- Informed by one of the most extensive translational and clinical datasets in CAR T, we are exploring a multitude of next-generation approaches, including in vivo and allogeneic (“off the shelf”) programs, dual antigen targeting, CAR T cells armed with custom payloads and gene editing. Our goal is to maximize the potential of cell therapy and reach more patients – across multiple platforms, diseases and targets – by expanding into areas with unmet need, such as solid tumors and autoimmune conditions.
With our bold ambition, and one of the broadest and most diverse CAR T portfolios in the world, we are leading the way to unlock the full promise of cell therapy as we strive to put more patients on the path to a cure.
Areas of interest include, but are not limited to, the following:
- Clinical-stage assets with transformative and differentiated clinical profile
- In vivo CAR approaches – including delivery platforms and assets
- Novel targets and binders
- Next-generation engineering (e.g., CAR logic gates, bolt-ons to overcome CT hurdles such as TME modulation and immune evasion)
- Viral and non-viral delivery for modifying cell gene expression
At Bristol Myers Squibb, hundreds of world-class researchers make up the Translational Medicine team, spanning all therapeutic areas of focus from early discovery to commercialization. Leveraging genomics, proteomics, imaging, and bioinformatics, these researchers bring forward new learnings and solutions in efforts to revolutionize treatment strategies for some of the most challenging diseases.
Areas of interest include, but are not limited to, the following:
- Innovative biomarker applications to inform target identification, disease characterization and treatment optimization:
- Diagnostic approaches to stratify/select patients most likely to benefit from therapy
- Pharmacodynamic assessment of dose monitoring and treatment response
- Biomarkers of emerging or novel clinical endpoints (e.g., minimal residual disease)
- Technologies and systems to elucidate disease biology (including the tumor microenvironment) and mechanisms of resistance
- Biomarker and bioanalytical technologies and platforms:
- Novel histopathology approaches; multiplexed fluorescence-based platforms and digital pathology and imaging analysis software applications
- Multicolored flow cytometry assays (exploratory and diagnostic grade), for both peripheral and tumoral assessment
- Proteomic technologies including high-resolution or high-plex applications
- Genomic-based platforms covering qPCR, ddPCR and NGS: gene expression profiling and tumor and germline DNA deep sequencing; spatial transcriptomics and single-cell RNAseq; methylation and epigenomic profiling; liquid biopsy applications (cfDNA and cfRNA)
- Novel radiomic imaging capabilities and alternate tracer platforms
At Bristol Myers Squibb, we combine deep understanding of human biology with advanced technologies and computational science to accelerate the discovery and development of innovative medicines.
We seek partnerships with academic innovators, technology developers and biotech companies whose breakthrough science and enabling technologies can expand our capabilities.
Next-generation discovery platforms
- Human biology, target discovery & validation: Human genetics, functional genomics and advanced profiling to understand disease biology and validate targets.
- Structural biology & molecular design: Experimental and computational approaches to accelerate molecular design and optimization.
- AI & computational discovery: AI and computational approaches to accelerate target discovery and therapeutic design.
Advanced modalities & biotherapeutics
- Targeted protein degradation & induced proximity: Targeted degradation, molecular glues and induced-proximity approaches to modulate disease-driving proteins.
- Multispecific & engineered biotherapeutics: Multispecifics, immune cell engagers, conditionally active therapeutics and other engineered biologics.
- Next-generation targeted conjugates: ADCs, differentiated payloads, degrader-antibody conjugates and other targeted conjugate approaches.
- RNA & programmable medicines: siRNA/RNAi, ASOs, mRNA, RNA editing and other RNA-based therapeutic approaches.
Cell and gene therapy enablers
- Next-generation cell therapy & engineering: Technologies that enhance therapeutic cell function, persistence, specificity and manufacturability.
- Gene delivery & engineering: Viral and nonviral technologies supporting genetic modification and next-generation cell and gene therapies.
Precision delivery
- Tissue- & cell-selective delivery: Targeted delivery technologies, including extrahepatic RNA/oligonucleotide and BBB/CNS delivery.
Human-relevant & translational models
- Human-relevant & predictive models: Human-relevant models to improve translation and predict therapeutic response.
Formulation & advanced drug delivery
- Formulation, bioavailability & stability: Technologies that improve formulation, stability, absorption and bioavailability across therapeutic modalities.
- Advanced & controlled delivery: Technologies enabling controlled, sustained or site-directed therapeutic delivery.